Skip to content
PubMed This is a summary of 14 peer-reviewed journal articles Updated
Gynecology · Genitourinary Syndrome of Menopause

Understanding Genitourinary Syndrome of Menopause (GSM)

At a Glance

Genitourinary Syndrome of Menopause (GSM), formerly called postmenopausal atrophic vaginitis, is a common condition caused by low estrogen levels. It causes vaginal dryness, tissue thinning, and urinary issues. Unlike hot flashes, GSM is progressive and worsens without treatment.

If you are experiencing vaginal dryness, irritation, or new urinary issues after menopause, you might feel like your body is suddenly behaving in ways you don’t understand. It is common to feel frustrated or even embarrassed, but what you are experiencing has a medical name: Genitourinary Syndrome of Menopause (GSM) [1].

For a long time, this was called “atrophic vaginitis,” but that name was misleading because it suggested the problem was only about inflammation in the vagina [2][3]. In reality, these changes affect the entire urogenital system—the complex network of tissues including the vulva, vagina, bladder, and urethra [3][4].

Why the Name Changed

The shift to the term Genitourinary Syndrome of Menopause was a deliberate move by medical experts to better reflect the reality of the condition [1].

  • More than the vagina: The old term ignored the urinary symptoms (like urgency or frequent UTIs) and external changes (vulvar irritation) that many women experience [2][3].
  • Not just inflammation: The suffix “-itis” implies a temporary infection or inflammation, whereas GSM describes a collection of symptoms caused by a long-term hormonal shift [2].
  • Anchored to menopause: The new name clearly links these changes to the natural decline of estrogen during the menopausal transition [3][4].

You Are Not Alone

If you feel like no one is talking about this, you’re right—but not because it’s rare. GSM is incredibly common, affecting up to 77% of postmenopausal women [5][6]. Despite how many people it affects, it is frequently under-reported and underdiagnosed [5][7]. Many women suffer in silence because they believe these changes are a “normal” part of aging that they must simply tolerate, or they feel a stigma attached to discussing urogenital health [7][8].

The Biological “Why”

The driver behind GSM is hypoestrogenism, which is the medical term for low estrogen levels [1][4]. Your urogenital tissues are highly sensitive to estrogen; when levels drop, several biological changes occur:

  • Tissue Thinning: The lining of the vagina and urethra becomes thinner, more fragile, and less elastic [9][4].
  • Reduced Lubrication: The natural moisture and blood flow to these areas decrease, leading to dryness and irritation [9].
  • Altered Balance: The healthy environment of the vagina changes, which can sometimes make the area more prone to infections or urinary discomfort [9][10].

A Chronic and Progressive Journey

It is vital to understand that GSM is different from other menopause symptoms like hot flashes [11]. While hot flashes often peak and then gradually fade away for many people, GSM is chronic and progressive [11][4].

“Progressive” means that without proactive management, the tissue changes typically do not resolve on their own; instead, they may continue to worsen over time as the body remains in a low-estrogen state [11][12]. This is why early recognition and communication with your healthcare provider are so important—treating the symptoms early can help preserve the health and function of these tissues for the long term [13][6].

You do not have to “just live with it.” Understanding that this is a recognized medical condition is the first step toward finding relief and improving your quality of life [14][6].

Common questions in this guide

What is the difference between atrophic vaginitis and GSM?
The term Genitourinary Syndrome of Menopause (GSM) replaced atrophic vaginitis because the condition affects the entire urogenital system, including the bladder and urethra. The new name also clarifies that symptoms are caused by menopausal hormonal changes, not a temporary infection.
Why do vaginal dryness and urinary issues happen after menopause?
These symptoms are driven by hypoestrogenism, or low estrogen levels. The tissues of the vulva, vagina, and urinary tract are highly sensitive to estrogen. When levels drop during menopause, these tissues become thinner, less elastic, and less lubricated.
Will my GSM symptoms eventually go away on their own?
Unlike hot flashes, which often fade over time, GSM is a chronic and progressive condition. Without proactive management, the tissue changes and symptoms like vaginal dryness and urinary urgency typically worsen as your body remains in a low-estrogen state.
How does a doctor diagnose Genitourinary Syndrome of Menopause?
Your healthcare provider can diagnose GSM by discussing your symptoms and performing a physical exam. They will look for specific signs of tissue thinning, reduced moisture, and altered vaginal balance to rule out other conditions like chronic yeast infections or UTIs.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my symptoms, do I meet the clinical criteria for Genitourinary Syndrome of Menopause (GSM)?
  2. 2.Could you perform a physical exam to look for specific signs of tissue thinning or changes in my urogenital health?
  3. 3.Are my urinary symptoms, like urgency or frequency, related to the same hormonal changes causing my vaginal dryness?
  4. 4.How can we differentiate my symptoms from other conditions like a chronic yeast infection or a urinary tract infection (UTI)?
  5. 5.Since GSM is a progressive condition, what are my options for long-term management to prevent these symptoms from worsening?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (14)
  1. 1

    The Genitourinary Syndrome of Menopause: An Overview of the Recent Data.

    Angelou K, Grigoriadis T, Diakosavvas M, et al.

    Cureus 2020; (12(4)):e7586 doi:10.7759/cureus.7586.

    PMID: 32399320
  2. 2

    What are the challenges in prescribing pharmacotherapy for female sexual dysfunctions?

    Nappi RE, Gardella B

    Expert opinion on pharmacotherapy 2019; (20(7)):777-779 doi:10.1080/14656566.2019.1582644.

    PMID: 30806100
  3. 3

    Genitourinary syndrome of menopause (GSM): recommendations from the Fifth International Consultation on Sexual Medicine (ICSM 2024).

    Simon JA, Nappi RE, Chedraui P, et al.

    Sexual medicine reviews 2026; (14(1)) doi:10.1093/sxmrev/qeaf055.

    PMID: 40981832
  4. 4

    Modern approach to the management of genitourinary syndrome in women with gynecological malignancies.

    Kovacevic N, Cilensek I, Merlo S, Segedin B

    Radiology and oncology 2023; (57(3)):292-298 doi:10.2478/raon-2023-0038.

    PMID: 37494601
  5. 5

    How to help patients navigate genitourinary syndrome of menopause.

    Trischuk T, Visentin J, Morissette R

    Canadian family physician Medecin de famille canadien 2024; (70(11-12)):710-714 doi:10.46747/cfp.701112710.

    PMID: 39638389
  6. 6

    Treating Genitourinary Syndrome of Menopause in Postmenopausal Women with a History of Breast Cancer.

    Ferguson D, Pederson H, Kling JM

    Drugs & aging 2026; (43(3)):211-221 doi:10.1007/s40266-026-01287-9.

    PMID: 41758440
  7. 7

    Update on Genitourinary Syndrome of Menopause: A Scoping Review of a Tailored Treatment-Based Approach.

    Cuccu I, Golia D'Augè T, Firulli I, et al.

    Life (Basel, Switzerland) 2024; (14(11)) doi:10.3390/life14111504.

    PMID: 39598302
  8. 8

    The Enablers and Barriers to Accessing Women's Health and Wellbeing Services for Women Aged 40-65 Years: A Qualitative Study.

    Simmons K, Hyde J, Harmanci D, et al.

    Community health equity research & policy 2026; (46(4)):413-431 doi:10.1177/2752535X251358919.

    PMID: 40653685
  9. 9

    The effect of pathophysiological changes in the vaginal milieu on the signs and symptoms of genitourinary syndrome of menopause (GSM).

    Qi W, Li H, Wang C, et al.

    Menopause (New York, N.Y.) 2020; (28(1)):102-108 doi:10.1097/GME.0000000000001644.

    PMID: 32810079
  10. 10

    Genitourinary syndrome of menopause: in their own words-development of a new patient-reported outcome measure.

    Kling JM, Faubion SS

    Menopause (New York, N.Y.) 2019; (26(4)):335-336 doi:10.1097/GME.0000000000001309.

    PMID: 30724847
  11. 11

    Women harmed by vaginal laser for treatment of GSM-the latest casualties of fear and confusion surrounding hormone therapy.

    Kaunitz AM, Pinkerton JV, Manson JE

    Menopause (New York, N.Y.) 2019; (26(4)):338-340 doi:10.1097/GME.0000000000001313.

    PMID: 30789455
  12. 12

    Genitourinary syndrome of menopause: effects on related factors, quality of life, and self-care power.

    Karakoç H, Uçtu AK, Özerdoğan N

    Przeglad menopauzalny = Menopause review 2019; (18(1)):15-22 doi:10.5114/pm.2019.84152.

    PMID: 31114453
  13. 13

    Addressing Vulvovaginal Atrophy (VVA)/Genitourinary Syndrome of Menopause (GSM) for Healthy Aging in Women.

    Nappi RE, Martini E, Cucinella L, et al.

    Frontiers in endocrinology 2019; (10()):561 doi:10.3389/fendo.2019.00561.

    PMID: 31496993
  14. 14

    The WISDOM survey: toward wiser care of women with vulvovaginal atrophy.

    Shifren JL

    Menopause (New York, N.Y.) 2019; (26(2)):115-117 doi:10.1097/GME.0000000000001281.

    PMID: 30531445

This page provides educational information about Genitourinary Syndrome of Menopause (GSM) and is not a substitute for professional medical advice. Always talk to your healthcare provider about your specific symptoms and long-term management options.

Get notified when new evidence is published on postmenopausal atrophic vaginitis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.